Analysts Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) PT at $13.14

Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) have received an average rating of “Hold” from the eight research firms that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $12.00.

Several equities research analysts have weighed in on JSPR shares. Royal Bank Of Canada set a $3.00 price target on shares of Jasper Therapeutics and gave the company a “sector perform” rating in a research report on Friday, May 15th. UBS Group began coverage on Jasper Therapeutics in a report on Monday, March 23rd. They issued a “neutral” rating for the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Jasper Therapeutics in a report on Tuesday, April 21st. Finally, TD Cowen cut shares of Jasper Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, May 15th.

Institutional Trading of Jasper Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. Acadian Asset Management LLC bought a new stake in Jasper Therapeutics in the 1st quarter worth approximately $46,000. Engineers Gate Manager LP purchased a new stake in Jasper Therapeutics in the second quarter worth about $78,000. Panagora Asset Management Inc. bought a new position in shares of Jasper Therapeutics in the fourth quarter worth about $35,000. Voleon Capital Management LP purchased a new position in shares of Jasper Therapeutics during the 3rd quarter valued at about $50,000. Finally, XTX Topco Ltd bought a new position in shares of Jasper Therapeutics during the 2nd quarter valued at approximately $152,000. Hedge funds and other institutional investors own 79.85% of the company’s stock.

Jasper Therapeutics Trading Up 13.0%

JSPR opened at $0.58 on Friday. The business’s 50-day moving average price is $0.65 and its 200-day moving average price is $1.08. Jasper Therapeutics has a 12 month low of $0.32 and a 12 month high of $3.84. The company has a market cap of $16.28 million, a P/E ratio of -0.18 and a beta of 3.07.

Jasper Therapeutics (NASDAQ:JSPR) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.08. Equities research analysts forecast that Jasper Therapeutics will post -1.67 earnings per share for the current fiscal year.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.